Sinovac Biotech Bangladesh Ltd

02/02/2026

EV71, a common cause of hand, foot, and mouth disease, affects 68% of Bangladeshi children. What does this high prevalence indicate?
🔗Read the paper:https://doi.org/10.1016/j.ijregi.2025.100739

14/01/2026

By taking care of life, we overcome any distance 🤝

12/01/2026

📌 Live Webinar 📌

Join us for an insightful and evidence-based discussion on influenza vaccination during pregnancy, featuring distinguished national and international experts.

Webinar on: “Preconception to Pregnancy: Vaccination Saves Two Lives."

🕘 Time: 9:00 PM – 10:00 PM, Today (Date: 12 January 2026

Speakers: Prof. Firoza Begum, President, OGSB & Dr. Eric GAO, Dr. Eric Gao, Head of International Medical Affairs, Sinovac Biotech Ltd., China.

Zoom Link: https://us06web.zoom.us/j/83247903836

📢 Do not miss this important academic discussion on maternal and fetal health.
Stay connected. Stay informed.

Webinar on “Preconception to Pregnancy: Vaccination Saves Two Lives” will be held on 12 January 2026 at 9:00 pm. Speakers: Prof. Firoza Begum, President, OGSB & Dr. Eric GAO, China. Pls Join, OGSB
Zoom Link: https://us06web.zoom.us/j/83247903836

01/01/2026

Happy New Year 2026!

30/12/2025

Advancing Protection Against Varicella-Zoster Virus (VZV)
At , we're committed to providing broader protection against VZV. We're proud to share key milestones achieved in 2025 for our varicella and shingles vaccine:
- Our Varicella Vaccine, Live demonstrated non-inferior immunogenicity in a head-to-head study, meeting WHO recommendations.
- Our Varicella Vaccine, Live has been approved in various countries, showcasing our expertise in process control and quality.
- Manufacturing Site of Varicella Vaccine, Live has passed the WHO PQ routine GMP inspection.
- Our Recombinant Zoster (Shingles) Vaccine (CHO cell) has received approval from the National Medical Products Administration (NMPA), marking a significant milestone in our fight against VZV.
These achievements underscore our dedication to advancing vaccine technology and improving global health outcomes.
This is the SINOVAC way of working: we provide vaccines to eliminate human diseases and promote a healthier world 🚀

Advancing Protection Against Varicella-Zoster Virus (VZV)

At , we're committed to providing broader protection against VZV. We're proud to share key milestones achieved in 2025 for our varicella and shingles vaccine:
- Our Varicella Vaccine, Live demonstrated non-inferior immunogenicity in a head-to-head study, meeting WHO recommendations.
- Our Varicella Vaccine, Live has been approved in various countries, showcasing our expertise in process control and quality.
- Manufacturing Site of Varicella Vaccine, Live has passed the WHO PQ routine GMP inspection.
- Our Recombinant Zoster (Shingles) Vaccine (CHO cell) has received approval from the National Medical Products Administration (NMPA), marking a significant milestone in our fight against VZV.

These achievements underscore our dedication to advancing vaccine technology and improving global health outcomes.

This is the SINOVAC way of working: we provide vaccines to eliminate human diseases and promote a healthier world 🚀

18/12/2025

🌟 Exciting Milestone in Influenza Protection 🌟
A recent clinical study marks significant progress in our ongoing fight against influenza: demonstrating that influenza vaccines (Split Virion) stimulate both humoral and cellular immune responses.
Influenza, or the ‘flu,’ is a highly contagious respiratory illness that spreads easily through the air or contaminated surfaces. While many cases are mild, the flu can cause severe complications, particularly in vulnerable populations.
Historically, influenza pandemics have occurred well before the 1918–19 outbreak. Today, annual flu vaccination remains the most effective strategy to prevent severe disease and reduce mortality caused by circulating strains. At SINOVAC, we are dedicated to advancing better solutions for influenza prevention.
Our latest publication in Nature Communications highlights promising findings: SINOVAC’s quadrivalent influenza vaccine (QIV) demonstrated a safety profile and antibody response comparable to existing QIVs, confirming non-inferior humoral responses.
While measuring influenza-specific cellular immune responses—crucial for long-term protection—is complex due to pre-existing T cells from previous exposures or vaccinations, our study goes beyond traditional humoral analysis. Using high-resolution immune profiling, we explored how our inactivated QIV elicits both humoral and cellular immunity. Although cellular responses were assessed in a subgroup, the data demonstrate that both QIVs induce robust immune responses in adults. Notably, Sinovac-QIV reduces T cell exhaustion and promotes follicular T cell clusters, potentially enhancing long-term immunity. —Providing valuable mechanistic insights into vaccine-induced protection.
This is : providing vaccines to eliminate human diseases and foster a healthier world. 🚀

02/12/2025

Exciting news! The National Medical Products Administration (NMPA) of China has approved SINOVAC's clinical trial application for its Recombinant Zoster (Shingles) Vaccine (CHO cell). This vaccine aims to prevent shingles in individuals aged 40 and above.
At , we are committed to the research, development, and commercialization of innovative vaccines. We have successfully established core R&D platforms for recombinant protein vaccines, novel adjuvants, and mRNA technologies.
Our Recombinant Zoster (Shingles) Vaccine (CHO cell) leverages advanced gene recombination technology and a proprietary composite adjuvant system, which can effectively stimulate the body to produce high levels of specific antibodies and cellular immune responses, demonstrating strong immunogenicity and durability.
We are dedicated to advancing public health and delivering future-ready solutions.

Exciting news! The National Medical Products Administration (NMPA) of China has approved SINOVAC's clinical trial application for its Recombinant Zoster (Shingles) Vaccine (CHO cell). This vaccine aims to prevent shingles in individuals aged 40 and above.

At , we are committed to the research, development, and commercialization of innovative vaccines. We have successfully established core R&D platforms for recombinant protein vaccines, novel adjuvants, and mRNA technologies.

Our Recombinant Zoster (Shingles) Vaccine (CHO cell) leverages advanced gene recombination technology and a proprietary composite adjuvant system, which can effectively stimulate the body to produce high levels of specific antibodies and cellular immune responses, demonstrating strong immunogenicity and durability.

We are dedicated to advancing public health and delivering future-ready solutions.

27/11/2025

SINOVAC has arrived in !
has signed a major agreement with the Minister of Health to transfer the technology for two vaccines, significantly strengthening Brazil's national vaccine production capacity.
These partnerships cover the Human Rabies and Varicella vaccines and represent a significant advance for Brazil’s national capacity in vaccine production.
Through this agreement:
- Tecpar will resume the manufacturing of the Human vaccine, a strategic immunobiological, currently 100% imported;
- The vaccine national production will bring greater autonomy, reducing dependence on international supply and reinforcing Brazil’s self-sufficiency in a high-demand vaccine.
At , we applaud the Brazilian government’s commitment to expanding national production and building autonomy in essential health technologies. We believe that access to vaccines must be comprehensive and equitable. Health only exists collectively—and we are proud to contribute to yet another historic step in strengthening Brazil’s exemplary public health system.
This milestone was announced during the Plenary Meeting of the Executive Group of the Health Economic-Industrial Complex ( ), with the presence of:
Alexandre Padilha, Minister of Health
Luciana Santos, Minister of Science, Technology and Innovation
Jarbas Barbosa, Director of PAHO-WHO and Regional Director of World Health Organization (WHO) for the
Leandro Safatle, President-Director of
Alongside numerous authorities and leaders from the health and industrial sectors.
Obrigada, Brasil!


https://www.facebook.com/share/p/1BnynKWLeV/

27/11/2025

SINOVAC’s partner in Brazil begins vaccine production.
Vice President of , Weining Meng, joins the first working meeting.
One day after the agreement was signed with ’s Ministry of Health, the Paraná Technology Institute (Tecpar) held the first joint meeting on November 25 to kick off the project for the local production of the human rabies vaccine, while the varicella vaccine will be produced through a separate partnership with another national laboratory.
Weining Meng joined the meeting during his visit to Brazil with the company’s delegation. The goal was to connect the Brazilian and Chinese teams and move forward with the commitments set for technology transfer.
This partnership between , , and the Ministry of Health is part of Brazil’s public healthcare system, known as SUS. It is one of the world’s largest government-funded systems and provides universal, free access to health services and vaccinations through the National Immunization Program.
The collaboration supports broader access to essential vaccines and strengthens disease prevention nationwide. And now we move into the phase that turns this agreement into real vaccine access for Brazilians.

26/11/2025

Is there an international standard to trust the safety of vaccines or medicines? Yes, it’s WHO prequalification (PQ).